nephrectomy within 70 days of diagnosis. Patients (n [ 3,340) who had a delay of 10 weeks were more likely to die compared with patients who had definitive surgery within 70 days (adjusted hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.15-1.33). This risk was not markedly attenuated after adjusting for confounding variables, including age, Charlson-Deyo score, pathologic stage, grade, and surgical margin status (adjusted HR 1.13; 95% CI 1.04-1.24). In multivariate linear regression analysis, treatment in academic or integrated network cancer center, lack of insurance, and median household income less than $38,000 are more like to have a delay greater than 70 days.
INTRODUCTION AND OBJECTIVES:
We have previously demonstrated widespread quality of care variations between hospitals for patients with renal cell carcinoma (RCC) utilizing a validated set of quality indicators (QI).
[1] However, the translation of this knowledge is limited by an incomplete understanding of the sources of this variation. Here we aimed to determine the relative contribution of surgeon versus hospital-level quality of care variations in order to inform the development of appropriate benchmarking strategies. Further, we sought to quantify the impact that hypothetical interventions on process-type indicators can have on outcome-type indicators.
METHODS: Patients undergoing nephrectomy for RCC were identified using linked population-level administrative databases in Ontario, Canada. Hospitals and individual surgeons were benchmarked according to previously validated RCC-specific QIs using indirect standardization1, adjusting performance for clinicopathological variables inherent to their patient populations. Inter-hospital and -surgeon level variation in each QI was assessed via mixed effect models and metaregression. Causal mediation analysis was employed to identify hospitals that could benefit from targeted quality improvement initiatives.
RESULTS: A total of 10,111 nephrectomy patients with complete clinical and pathological data were identified between 1995 to 2014. Care was provided by 393 surgeons across 138 hospitals. After adjustment for case-mix, a total of 3-25% of surgeons and 4-32% of hospitals were statistically significant outliers for a given QI, performing worse than the provincial average. Significant variation at both hospital and surgeon levels was observed for four of the five indicators (P<0.001). Surgeon-level variance was equal to or greater than hospital-level in four of five indicators. The causal mediation analysis identified hospitals where improvements in minimally invasive surgery rates could translate to shorter average length of stay.
CONCLUSIONS: Both surgeon-and hospital-level effects contribute to the observed variance in quality of care received by patients undergoing surgery for RCC. Further, we demonstrate the feasibility of identifying hospitals for targeted quality improvement interventions through causal mediation analysis. Collectively, these data demonstrate the utility of QI variance decomposition and mediation analysis methods for informing the development of datadriven quality benchmarking strategies for RCC. 
The appropriate duration of postoperative renal cell carcinoma (RCC) surveillance remains unknown. Guidelines often leave discontinuation to provider discretion. Herein, we investigate when surveillance may be discontinued by estimating when risk of non-RCC death exceeds the risk of RCC recurrence.
METHODS: We identified 1672 patients who underwent surgery for M0 RCC between 1999-2018. Patients were stratified by pathologic stage (pT1aN0-x, pT1bN0-x, pT2N0-x, pT3aN0-x, pT3b/c/ 4N0-x), histology (clear cell, papillary and chromophobe), age, and ECOG status (0,1,2-4). Using a competing risks analysis, cumulative incidence functions were estimated for RCC recurrence and non-RCC death using the Fine and Gray proportional subhazards model. Surveillance duration was estimated as the time point in which the cumulative incidence of non-RCC death exceeded that of RCC recurrence for a given stage, histology, age and ECOG score.
RESULTS: At a median follow-up of 2.1 years (IQR 0.6-5.1 years), a total of 272 (16.3%) recurrences and 234 (14.0%) non-RCC deaths had occurred. The fitted model showed significant associations for stage with recurrence and for age and ECOG with non-RCC death, which resulted in different estimated durations. For example, for patients age 50 with pT1aN0-x clear cell and ECOG 0 the incidence of non-RCC death exceeded that of recurrence after 4.4 years (Fig) . However, when ECOG status was 1 or 2-4 (Fig) or the patient age 70, regardless of ECOG status (data not shown), the incidence of non-RCC death exceeded that of recurrence at 30 days following surgery, suggesting that routine oncologic surveillance may not be necessary. Alternatively, for patients age 50 with >[pT3aN0-x clear cell, regardless of ECOG status, incidence of non-RCC death failed to exceed that of recurrence for >15 years (Fig) , suggesting longer surveillance than currently recommended.
CONCLUSIONS: Modeling competing risks of RCC recurrence and non-RCC death, we estimated time points when routine RCC surveillance may be reasonably discontinued. These estimates may allow providers and patients to make informed decisions regarding when the focus of care can transition to more significant health conditions.
